bFGF and VEGF synergistically enhance endothelial cytoprotection via decay-accelerating factor induction

American Journal of Physiology - Cell Physiology

Volumn 282, Issue 3 51-3, 2002, Pages

  Mason, Justin C ^a   Lidington, Elaine A ^a   Ahmad, Saifur R ^a   Haskard, Dorian O ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Complement; Complement mediated injury

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; COMPLEMENT COMPONENT C3; DECAY ACCELERATING FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PROTEIN P44; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL PROLIFERATION; CELL PROTECTION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIUM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NORTHERN BLOTTING; PRIORITY JOURNAL;

EID: 0036087022     PISSN: 03636143     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpcell.00339.2001     Document Type: Article

References (54)

1. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo
2. Decay-accelerating factor is present on cultured human umbilical vein endothelial cells
3. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis
4. Relative inefficiency of terminal complement activation
5. Biological roles of fibroblast growth factor-2
6. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement mediated lysis
7. Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins
8. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
9. Laboratory-clinical correlates of time-associated lesions in the vascular immunopathology of human cardiac allografts
10. VEGF: An update on biological and therapeutic aspects
11. Angiogenesis in cancer, vascular, rheumatoid and other disease
12. v integrins
13. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells
14. Angiogenic growth factors: Potential new treatment for acute myocardial infarction?
15. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels
16. Therapeutic angiogenesis in ischemic heart disease
17. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization
18. Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation
19. bcl-2 gene prevents apoptosis of basic fibroblast growth factor-deprived murine aortic endothelial cells
20. Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury
21. Regulatory proteins of complement
22. Decay-accelerating factor: Biochemistry, molecular biology and function
23. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent upon endogenous basic fibroblast growth factor
24. Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor-a mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis
25. Expression and regulation of complement regulatory proteins CD59 and decay-accelerating factor (DAF) on endothelial cells
26. Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition
27. Human Thy-1 is cytokine inducible on vascular endothelial cells and is a signaling molecule regulated by protein kinase C
28. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury
29. Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement
30. Complement membrane attack on nucleated cells: Resistance, recovery and non-lethal effects
31. Regulation of the complement membrane attack pathway
32. Complement activation and atherosclerosis
33. Decay-accelerating factor regulates complement-mediated damage in the human atherosclerotic wall
34. Autoantibodies against modified low density lipoprotein. Nonlipid factor of blood plasma that stimulates foam cell formation
35. Basic fibroblast growth factor is cardioprotective in ischemia-reperfusion injury
36. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro
37. Atherosclerosis - An inflammatory disease
38. Complement-mediated regulation of tissue factor activity in endothelium
39. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: An autocrine mechanism contributing to angiogenesis
40. Complement receptors and regulatory proteins in human atherosclerotic lesions
41. Decay-accelerating factor is expressed on vascular smooth muscle cells in human atherosclerotic lesions
42. Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions
43. Fluid shear stress inhibits TNF-alpha activation of JNK but not ERK1/2 or p38 in human umbilical vein endothelial cells: Inhibitory crosstalk among MAPK family members
44. Roles of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in the signal transduction of basic fibroblast growth factor in endothelial cells during angiogenesis
45. Complement-endothelial cell interactions: Pathophysiological implications
46. Processes in atherogenesis: Complement activation
47. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion
48. Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque
49. Complement. First of two parts
50. Angiogenesis in ischemic heart disease
51. A monoclonal antibody that detects a novel antigen on endothelial cells that is induced by tumor necrosis factor, IL-1, or lipopolysaccharide
52. Characterization of vascular endothelial cell growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth
53. Generation of C-reactive protein and complement components in atherosclerotic plaques
54. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor